MR Contrast Agents: Safety Considerations and Clinical Practices
Credits: 1.0 Category A, ARRT credit | 1.0 AHRA CRA credit
CE Effective Date: November 22, 2021 | CE Expiration Date: December 31, 2026
Format: Self Instructional - Audio Visual, Video with Slides
Supported by GE Healthcare
In this Expert Forum, Dr. Lawrence Tanenbaum, MD, FACR, will review the classification of Gadolinium MR contrast agents according to their molecular structure, ionicity, and stability. The impact of these properties and supporting clinical data for safety considerations in choosing an agent will be discussed with the goal of providing insight that can be applied in everyday clinical practice. Following the presentation questions from the audience were addressed in a moderated Q&A session.
To participate select the appropriate profession below.